Reported Earnings • Jun 05
Full year 2025 earnings released: UK£0.028 loss per share (vs UK£0.004 profit in FY 2024) Full year 2025 results: UK£0.028 loss per share (down from UK£0.004 profit in FY 2024). Revenue: UK£1.70m (down 88% from FY 2024). Net loss: UK£9.07m (down UK£10.4m from profit in FY 2024). Announcement • Jun 05
Futura Medical plc, Annual General Meeting, Jun 29, 2026 Futura Medical plc, Annual General Meeting, Jun 29, 2026. Location: the offices of panmure liberum, ropemaker place, 25 ropemaker street, ec2y 9ly, london United Kingdom New Risk • Apr 29
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Shareholders have been substantially diluted in the past year (91% increase in shares outstanding). Market cap is less than US$10m (UK£5.17m market cap, or US$6.97m). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Announcement • Apr 20
Futura Medical plc to Report Fiscal Year 2025 Results on Apr 29, 2026 Futura Medical plc announced that they will report fiscal year 2025 results at 8:00 AM, GMT Standard Time on Apr 29, 2026 New Risk • Apr 19
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (91% increase in shares outstanding). Market cap is less than US$10m (UK£6.73m market cap, or US$9.09m). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Share price has been volatile over the past 3 months (9.3% average weekly change). Announcement • Mar 23
Futura Medical plc Reports Positive Results from Eroxon and Eroxon Intense Home User Test Futura Medical plc reported the results of the Home User Test conducted on the current Eroxon product and prototype product Eroxon 'Intense'. The results of the HUT are positive (with an overall improvement on the original Phase 3 study for Eroxon) and give the Company confidence that the Intense formula gives a statistically significant greater sensorial effect over the current Eroxon formulation especially in the first two minutes after application. The study compared the new Intense formula with current Eroxon over 4 weeks in 223 subjects (112 tested Eroxon and 111 tested Intense). Subjects were based in the United Kingdom and were recruited on-line. Each subject was individually interviewed to assess their suitability for inclusion into the study. Subjects were male, 18-59 years of age and 94% assessed as suffering from mild to moderate erectile dysfunction. In this selected demographic, both Eroxon and Intense were judged to have high efficacy rates. Subjects stated that they were satisfied with the hardness of their erection in 70% and 71% of their sexual encounters using Eroxon or Intense, respectively. Subjects also recorded that their erections lasted long enough to have sexual intercourse in 84% and 85% of encounters, respectively. Using the clinically validated and most widely used measure of erection functionality (the IIEF-EF scale), subjects in both groups showed a highly significant and clinically important improvement in their erectile function. The improvement versus baseline (pre-treatment) was at least as good as reported in the Phase 3 clinical study FM71, which was used to obtain regulatory approval in the US. The study also showed that when either Eroxon or Intense was applied onto the study participant by their partner it increased effectiveness and showed significantly higher erection maintenance. The study confirmed the sensorial enhancement of Intense over Eroxon with statistically significant greater intensity during the first two minutes after application. Additionally, both products were well tolerated in men and their female partners. Both formulations received favourable 4- or 5-star ratings in 49% and 53% of subjects for Eroxon and the Intense formula respectively. Over 50% of study participants said they would be somewhat or very likely to purchase either product. In summary, the HUT study confirmed that a more targeted approach of marketing to consumers under 60 years of age with mild to moderate ED will likely lead to higher efficacy and satisfaction rates and thus higher in-market repeat purchase rates. Encouraging users to use the product with their partners as part of foreplay will likely also improve the overall product experience. The Intense formula will appeal to those consumers seeking a more rapid or stronger sensorial effect, especially in younger age groups. Detailed work is now underway to assess and update optimal brand positioning. Meanwhile, data necessary to support regulatory filings for Eroxon Intense in Europe and USA has been generated and a 'Special' 510K submission has been filed with the US FDA. Regulatory authorisation in the US and Europe is expected in H1 2026. Announcement • Jan 12
Futura Medical Announces Positive Results from WSD4000 Early Feasibility Study Futura Medical reported positive results of the WSD4000 Early Feasibility Study ('EFS') which comprised of 12 women suffering from some degree of sexual dysfunction. The positive trends and high response metrics demonstrate that the product has the potential to deliver a significant improvement in impaired sexual function in women. Given the lack of known regulatory-approved OTC treatment available for this condition in women, this represents a significant opportunity for WSD4000 globally. Whilst the size of the EFS study was relatively modest, the results are highly encouraging and give the Company confidence to proceed to the next steps of designing a Phase 3 clinical study which will be further informed by a small in-clinic sham /placebo controlled sensory study (results expected in mid 2026), and a 200 subject home user study (results expected in mid2026). Using the internationally recognised Total Female Sexual Function Index ('FSFI') scale, a highly statistically significant improvement over baseline was achieved in overall sexual function; On average, an improvement in overall sexual function of 6.35 units over baseline (pre-treatment) in the FSFI scale was achieved which exceeded the minimal clinically important difference of 4 units defined by expert scientific consensus; Statistically significant improvements were achieved in five of the six FSFI domains: sexual arousal, lubrication, pain improvement, ability to orgasm and sexual satisfaction; Judged to be effective in both pre- and post-menopausal women; Using the Female Sexual Encounter Profile ('FSEP') metrics, meaningful improvements were achieved in all measures across the 56 sexual encounters recorded: 64.2% of uses were described as experiencing moderate or high desire; 83.9% of uses reported satisfaction with arousal; 71.4% of uses reported enough lubrication for comfortable intercourse; 69.6% of uses resulted in orgasm; 78.6% of uses reported moderate or high arousal; 91.1% reported conditions appropriate for a satisfactory sexual encounter; Every use of the gel (56 in total) resulted in a genital sensation which occurred on average in less than five minutes in 9 out of 10 uses; The product was well tolerated. 58% subjects experienced a mild to moderate but transient "burning" sensation which in general led to higher efficacy levels indicating that subjects regarded this as a sensory signal that "the product was working". No subjects discontinued use of the product. The EFS of the WSD4000 prototype followed the Food and Drug Administration's ('FDA') guidance from a recent pre-submission meeting and was conducted to Good Clinical Practice ('GCP') standards and ethical principles for medical research. An EFS study was defined by FDA as a pre-requisite for the first in class (De Novo) medical device with OTC classification. 12 subjects were recruited into the study with 11 completing all elements: five pre-menopausal and six post-menopausal. After initial screening for suitability, subjects were formally diagnosed by using the FSFI instrument which is a fully validated self-completed questionnaire that has become the gold standard and most widely used measuring instrument in this scientific field1. In addition, only one in four women seek professional help and despite their efforts, many women continue to struggle with symptoms of sexual dysfunction with few women (13%) experiencing an improvement in symptoms over time and 37% getting worse over time3. New Risk • Dec 14
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 91% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (23% average weekly change). Shareholders have been substantially diluted in the past year (91% increase in shares outstanding). Market cap is less than US$10m (UK£6.74m market cap, or US$9.01m). Board Change • Dec 08
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Gordon Davis was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Dec 06
Futura Medical PLC Announces Resignation of Harmesh Suniara as Non-Executive Director, Effective December 3, 2025 Futura Medical PLC announced that following the passing of resolutions in respect to the recently announced placing and subscription, and significant reduction in Lombard Odier Asset Management's percentage shareholding in Futura following the upcoming admission of the placing shares and subscription shares to trading on AIM, Harmesh Suniara is stepping down from his role as Non-Executive Director and will step off the Board with immediate effect. Harmesh was appointed to the Board as Lombard Odier Asset Management's representative in March 2025. Announcement • Nov 13
Futura Medical plc has completed a Follow-on Equity Offering in the amount of £2.75 million. Futura Medical plc has completed a Follow-on Equity Offering in the amount of £2.75 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 261,800,000
Price\Range: £0.01
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 13,200,000
Price\Range: £0.01
Transaction Features: Subsequent Direct Listing New Risk • Oct 07
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: UK£7.13m (US$9.57m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (23% average weekly change). Market cap is less than US$10m (UK£7.13m market cap, or US$9.57m). Reported Earnings • Oct 05
First half 2025 earnings released: UK£0.022 loss per share (vs UK£0.003 profit in 1H 2024) First half 2025 results: UK£0.022 loss per share (down from UK£0.003 profit in 1H 2024). Revenue: UK£1.00m (down 86% from 1H 2024). Net loss: UK£6.59m (down UK£7.59m from profit in 1H 2024). Revenue is expected to decline by 4.9% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in the United Kingdom are expected to grow by 5.5%. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 56% per year, which means it is significantly lagging earnings. Announcement • Sep 19
Futura Medical plc to Report First Half, 2025 Results on Sep 30, 2025 Futura Medical plc announced that they will report first half, 2025 results on Sep 30, 2025 Reported Earnings • Jun 02
Full year 2024 earnings: EPS and revenues exceed analyst expectations Full year 2024 results: EPS: UK£0.004 (up from UK£0.022 loss in FY 2023). Revenue: UK£13.9m (up 349% from FY 2023). Net income: UK£1.29m (up UK£7.81m from FY 2023). Profit margin: 9.3% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Revenue exceeded analyst estimates by 4.8%. Earnings per share (EPS) also surpassed analyst estimates by 141%. Revenue is expected to decline by 29% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in the United Kingdom are expected to grow by 5.0%. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings. Announcement • May 27
Futura Medical plc, Annual General Meeting, Jun 19, 2025 Futura Medical plc, Annual General Meeting, Jun 19, 2025. Location: the offices of panmure liberum, ropemaker place, 25 ropemaker street, ec2y 9ly, london United Kingdom Price Target Changed • Apr 15
Price target decreased by 21% to UK£1.00 Down from UK£1.26, the current price target is an average from 3 analysts. New target price is 937% above last closing price of UK£0.096. Stock is down 73% over the past year. The company is forecast to post earnings per share of UK£0.024 for next year compared to UK£0.0043 last year. Announcement • Apr 10
Futura Medical plc to Report Fiscal Year 2024 Results on Apr 15, 2025 Futura Medical plc announced that they will report fiscal year 2024 results at 8:00 AM, GMT Standard Time on Apr 15, 2025 Announcement • Mar 31
Futura Medical plc Appoints Harmesh Suniara to the Board as Non-Executive Director, Immediate Effective Futura Medical plc announced the appointment of Harmesh Suniara to the Board as a Non-executive Director, with immediate effect. Harmesh has over 17 years' experience of working in investment management, with a particular focus on UK small and mid-cap equities. Since 2017 he has worked as a Portfolio Manager at Lombard Odier Asset Management (Europe) Limited, and from 2007, he was an Investment Manager at Henderson Volantis Capital and Gartmore Investment Management. The following disclosures in relation to the appointment of Harmesh Kumar Suniara, aged 54, are required pursuant to Schedule 2(g) of the AIM Rules for Companies: Current: C4X Discovery Holdings Limited, IQE Plc and Actual Experience Plc. Harmesh Suniara was a Director at Actual Experience Plc, which entered administration on 14 November 2023. New Risk • Mar 30
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (15% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (UK£31.8m market cap, or US$41.1m). Breakeven Date Change • Jan 31
Forecast breakeven date pushed back to 2025 The 3 analysts covering Futura Medical previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of UK£7.13m in 2025. Average annual earnings growth of 189% is required to achieve expected profit on schedule. New Risk • Jan 30
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risk Less than 1 year of cash runway based on current free cash flow (-UK£4.2m). Announcement • Jan 15
Futura Medical plc Announces Positive Results from WSD4000 Home User Study Futura Medical plc announced the successful completion and positive results of the WSD4000 Home User study for the treatment of sexual dysfunction in women. WSD4000 Home User study results: The 'sensory'1 study, which comprised 67 women suffering from some degree of sexual dysfunction, delivered an overall positive change in sexual function after four weeks. The majority of respondents reported increased vaginal lubrication, increased genital sensation, improved genital pleasure and an improvement in their satisfaction with the sexual experience. 57% of women used the product on more occasions than the stated minimum which is a strong indication of the respondents' positive response to the product. In those that experienced some degree of sexual dysfunction, there was a notable uplift from the baseline with positive responses in arousal, lubrication, orgasm, satisfaction and discomfort (pain). Following the success of the study, alongside market research on the size of the opportunity following commercialization, the Board is recommending to proceed with an Early Feasibility Study during first half of 2025. This will enable the Company to consider refinements to the methodology in a population more representative of the target user and therefore hope to increase efficacy still further, as well as further inform on perceptions of the product. New Risk • Sep 11
New minor risk - Financial position The company has less than a year of cash runway based on its current free cash flow. Free cash flow: -UK£4.2m This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-UK£4.2m). Share price has been volatile over the past 3 months (7.1% average weekly change). New Risk • Sep 02
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Revenue is less than US$5m (UK£3.1m revenue, or US$4.1m). Announcement • Sep 02
Futura Medical plc Announces Update on Us Launch Eroxon's Availability on Amazon and in Stores Futura Medical plc announced that as part of Haleon's launch plan, as of 1 September 2024, Eroxon is available for pre-order online for delivery in October and will also be available in stores in the US from October 2024. Announcement • Aug 19
Futura Medical plc to Report First Half, 2024 Results on Sep 10, 2024 Futura Medical plc announced that they will report first half, 2024 results on Sep 10, 2024 Announcement • May 26
Futura Medical plc, Annual General Meeting, Jun 20, 2024 Futura Medical plc, Annual General Meeting, Jun 20, 2024. Location: the offices of liberum capital limited, ropemaker place, 25 ropemaker street, ec2y 9ly, london United Kingdom New Risk • Apr 05
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (16% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (4.6% increase in shares outstanding). Revenue is less than US$5m (UK£1.7m revenue, or US$2.2m). Announcement • Mar 25
Futura Medical plc to Report Fiscal Year 2023 Results on Apr 10, 2024 Futura Medical plc announced that they will report fiscal year 2023 results on Apr 10, 2024 New Risk • Jan 18
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£3.0m net loss next year). Shareholders have been diluted in the past year (4.6% increase in shares outstanding). Revenue is less than US$5m (UK£1.7m revenue, or US$2.2m). Announcement • Jan 09
Futura Medical plc Announces Appointment of Roy Davis as Non-Executive Director Futura Medical plc announced the appointment of Roy Davis as a Non-Executive Director with immediate effect. Roy brings a wealth of commercial experience in medical devices companies and has a proven track record of successfully scaling companies and delivering substantial value for shareholders. He has held leadership positions at a number of publicly quoted med tech companies, including CEO of Optos plc, from 2008 to 2016 until its sale to Nikon for £259 million in February 2015. From 2007 to 2008, Roy was CEO of Gyrus Group plc, until its acquisition by Olympus Corporation in 2008 for $1.9 billion. He is currently Non-Executive Chair at LungLife AI plc and Rair Health Ltd. and was until recently, Non-Executive Chair at Medica Group plc until its acquisition by IK Partners for £269 million earlier this year. On 7 December it was announced that Roy will become a Non-Executive Director and Chair Designate of Inspiration Healthcare Group plc with effect from 25 January 2024. New Risk • Nov 02
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£3.0m net loss next year). Share price has been volatile over the past 3 months (7.4% average weekly change). Shareholders have been diluted in the past year (4.5% increase in shares outstanding). Revenue is less than US$5m (UK£1.7m revenue, or US$2.1m). New Risk • Oct 31
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: UK£81.2m (US$98.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£3.0m net loss next year). Shareholders have been diluted in the past year (4.5% increase in shares outstanding). Revenue is less than US$5m (UK£1.7m revenue, or US$2.1m). Market cap is less than US$100m (UK£81.2m market cap, or US$98.5m). Announcement • Oct 26
Eroxon® Granted Marketing Authorisation in Mexico Futura Medical plc announces that the Mexican Secretariat of Healthhas granted over the counter sale ("OTC") Marketing Authorisation for Eroxon®, the Company's break through, topical gel formulation for the treatment of erectile dysfunction ("ED"). Eroxon® can now be marketed in Mexico as a topical treatment for ED available OTC without the need for a prescription. Eroxon® is approved as an effective, clinically proven treatment for ED with a 10-minute onset of action. The prevalence of ED disrupts the lives of at least 1 in 5 men globally. Mexico currently has a population of 129 million. MED3000 has already been approved as the first pan-European clinically proven topical treatment for ED available OTC and is now available in a growing number of EU and Middle East markets. Initial launches commenced under the brand name Eroxon®in March 2023, with commercial agreements in key markets including the European Economic Area, UK, Switzerland, South Korea, Latin America and the Middle East. Announcement • Aug 18
Futura Medical plc to Report First Half, 2023 Results on Sep 18, 2023 Futura Medical plc announced that they will report first half, 2023 results on Sep 18, 2023 Board Change • Jul 21
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Senior Independent Non-Executive Director Andrew Unitt was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Jul 21
Futura Medical plc Announces Board Changes Futura Medical plc announced that Non-Executive Chairman, John Clarke has stepped down and is succeeded by existing Non-Executive board member, Jeff Needham. John joined Futura on 1 November 2011 and has been instrumental in driving the Company's strategy and success in securing commercial partnerships.His departure is part of a planned transition with Independent Non-Executive Director, Jeff succeeding John as Chairman. Jeff has been a Non-Executive Director of the Company since October 2021. A search for a new Non-Executive Director is underway and an announcement will be made in due course. The Company continues its progress in a pivotal year of success in broadening the distribution and availability of MED3000 across different markets, worldwide. New Risk • Jun 14
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 4.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Less than 1 year of cash runway based on current free cash flow (-UK£6.5m). Share price has been volatile over the past 3 months (7.9% average weekly change). Shareholders have been diluted in the past year (4.1% increase in shares outstanding). Announcement • Jun 13
Futura Medical plc's Fast-Acting Topical Gel for the Treatment of Erectile Dysfunction Futura Medical plc announced that the US Food and Drug Administration has granted over the counter sale Marketing Authorisation for MED3000, the Company's breakthrough, topical gel formulation for the treatment of erectile dysfunction as a De Novo Medical Device. MED3000 can now be legally marketed in the USA as the first topical treatment for ED available OTC without the need for a prescription. MED3000 is approved as an effective, clinically proven treatment for ED with a 10-minute onset of action. Oral medications such as Cialis and Viagra require a doctor's prescription in the USA and typically are required to be taken at least 30 minutes in advance. MED3000 has already been approved as the first pan-European clinically proven topical treatment for ED available O TC and is now available in Belgium and the UK. Initial launches commenced under the brand name Eroxon in March 2023 with further launches planned through 2023 and beyond commercial agreements in key markets including the European Economic Area, UK, Switzerland, South Korea, Latin America and Middle East. Announcement • May 27
Futura Medical plc, Annual General Meeting, Jun 22, 2023 Futura Medical plc, Annual General Meeting, Jun 22, 2023, at 09:00 Coordinated Universal Time. Location: The offices of Liberum Capital, Ropemaker Place 25 Ropemaker Street, London United Kingdom Agenda: To receive and adopt the annual report of the directors and the financial statements for the financial year ended 31 December 2022 and the report of the appointed auditors thereon; to re-elect John Clarke as a Director of the Company, who retires by rotation in accordance with the Company's articles of association; to re-appoint Grant Thornton UK LLP as auditor of the Company to hold office until the conclusion of the next annual general meeting of the Company; to authorise the Directors to determine the remuneration of Grant Thornton UK LLP as auditor of the Company; and to consider other matters. Price Target Changed • Nov 16
Price target increased to UK£1.21 Up from UK£1.09, the current price target is provided by 1 analyst. New target price is 203% above last closing price of UK£0.40. Stock is up 15% over the past year. The company is forecast to post a net loss per share of UK£0.019 next year compared to a net loss per share of UK£0.018 last year. Price Target Changed • Aug 31
Price target increased to UK£1.21 Up from UK£1.04, the current price target is provided by 1 analyst. New target price is 185% above last closing price of UK£0.42. Stock is up 9.7% over the past year. The company posted a net loss per share of UK£0.018 last year. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 5 non-independent directors. Independent Non-Executive Chairman John Clarke was the last independent director to join the board, commencing their role in 2012. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Price Target Changed • Mar 20
Price target increased to UK£0.64 Up from UK£0.58, the current price target is provided by 1 analyst. New target price is 40% above last closing price of UK£0.46. Stock is up 454% over the past year. Is New 90 Day High Low • Mar 05
New 90-day high: UK£0.21 The company is up 49% from its price of UK£0.14 on 04 December 2020. The British market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 11% over the same period. Is New 90 Day High Low • Feb 19
New 90-day high: UK£0.20 The company is up 44% from its price of UK£0.14 on 20 November 2020. The British market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 10.0% over the same period. Reported Earnings • Sep 18
First half earnings released Over the last 12 months the company has reported total losses of UK£5.52m, with losses narrowing by 34% from the prior year.